1
|
Lastraioli E, Boni L, Romoli MR, Crescioli S, Taddei A, Beghelli S, Tomezzoli A, Vindigni C, Saragoni L, Messerini L, Bernini M, Bencini L, Giommoni E, Freschi G, Di Costanzo F, Scarpa A, Morgagni P, Farsi M, Roviello F, De Manzoni G, Bechi P, Arcangeli A. VEGF-A clinical significance in gastric cancers: immunohistochemical analysis of a wide Italian cohort. Eur J Surg Oncol 2014; 40:1291-8. [PMID: 24784776 DOI: 10.1016/j.ejso.2014.03.028] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2013] [Revised: 03/29/2014] [Accepted: 03/31/2014] [Indexed: 12/20/2022] Open
Abstract
PURPOSE The clinical significance of VEGF-A expression in gastric cancer (GC) has been reported with contradicting results. We analyzed the expression and clinical significance of VEGF-A in a wide Italian cohort of GC specimens. METHODS VEGF-A expression was tested by immunohistochemistry in 507 patients with GC of all clinical stages. The impact of VEGF-A on overall survival (OS) was evaluated in conjunction with clinical and pathological parameters. RESULTS In the Italian cohort we studied VEGF-A was not an independent prognostic factor neither at the univariate nor at multivariate analysis. CONCLUSIONS Although frequently expressed, in our study VEGF-A was not able to discriminate between groups of patients with different risk.
Collapse
Affiliation(s)
- E Lastraioli
- Department of Clinical and Experimental Medicine, University of Florence, Largo GA Brambilla 3, 50134 Florence, Italy
| | - L Boni
- Clinical Trials Coordinating Center, Azienda Ospedaliero-Universitaria Careggi/Istituto Toscano Tumori, Largo GA Brambilla 3, 50134 Florence, Italy
| | - M R Romoli
- Department of Clinical and Experimental Medicine, University of Florence, Largo GA Brambilla 3, 50134 Florence, Italy
| | - S Crescioli
- Department of Clinical and Experimental Medicine, University of Florence, Largo GA Brambilla 3, 50134 Florence, Italy
| | - A Taddei
- Surgery and Translational Medicine, University of Florence, Largo GA Brambilla 3, 50134 Florence, Italy
| | - S Beghelli
- Department of Pathology and Diagnostics, University of Verona, Piazzale LA Scuro 10, 37134 Verona, Italy
| | - A Tomezzoli
- Pathology Division, Borgo Trento Hospital, Piazzale A Stefani 1, 37134 Verona, Italy
| | - C Vindigni
- Pathology Division, Azienda Ospedaliero-Universitaria Senese, Viale M Bracci 16, 53100 Siena, Italy
| | - L Saragoni
- Pathology Division, Morgagni-Pierantoni Hospital, Via C Forlanini 34, 47121 Forlì, Italy
| | - L Messerini
- Department of Clinical and Experimental Medicine, University of Florence, Largo GA Brambilla 3, 50134 Florence, Italy
| | - M Bernini
- General Surgery and Surgical Oncology, Azienda Ospedaliero-Universitaria Careggi, Largo GA Brambilla 3, 50134 Florence, Florence, Italy
| | - L Bencini
- General Surgery and Surgical Oncology, Azienda Ospedaliero-Universitaria Careggi, Largo GA Brambilla 3, 50134 Florence, Florence, Italy
| | - E Giommoni
- Medical Oncology, Azienda Ospedaliero-Universitaria Careggi, Largo GA Brambilla 3, 50134 Florence, Florence, Italy
| | - G Freschi
- Surgery and Translational Medicine, University of Florence, Largo GA Brambilla 3, 50134 Florence, Italy
| | - F Di Costanzo
- Medical Oncology, Azienda Ospedaliero-Universitaria Careggi, Largo GA Brambilla 3, 50134 Florence, Florence, Italy
| | - A Scarpa
- Department of Pathology and Diagnostics, University of Verona, Piazzale LA Scuro 10, 37134 Verona, Italy
| | - P Morgagni
- General Surgery, Morgagni-Pierantoni Hospital, Via C Forlanini 34, 47121 Forlì, Italy
| | - M Farsi
- General Surgery and Surgical Oncology, Azienda Ospedaliero-Universitaria Careggi, Largo GA Brambilla 3, 50134 Florence, Florence, Italy
| | - F Roviello
- Department of General Surgery and Oncology, University of Siena, Viale M Bracci 16, 53100 Siena, Italy
| | - G De Manzoni
- Division of Surgery, University of Verona, Piazzale LA Scuro 10, 37134 Verona, Italy
| | - P Bechi
- Surgery and Translational Medicine, University of Florence, Largo GA Brambilla 3, 50134 Florence, Italy
| | - A Arcangeli
- Department of Clinical and Experimental Medicine, University of Florence, Largo GA Brambilla 3, 50134 Florence, Italy.
| |
Collapse
|
2
|
Bria E, De Manzoni G, Beghelli S, Tomezzoli A, Barbi S, Di Gregorio C, Scardoni M, Amato E, Frizziero M, Sperduti I, Corbo V, Brunelli M, Bersani S, Tortora G, Scarpa A. A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. Ann Oncol 2012; 24:693-701. [PMID: 23131390 DOI: 10.1093/annonc/mds506] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND To obtain a prognostic stratification model for resected gastric cancer patients. PATIENTS AND METHODS Clinicopathological and molecular data (expression of Cdx2, Apc, β-catenin, E-cadherin, Fhit, p53, and human epidermal growth factor receptor-2 (Her2); HER2 and TOPO2A gene copy number; PIK3CA mutations; microsatellite instability) were correlated to cancer-specific/overall survival (CSS/OS) using a Cox model. Individual patient probability (IPP) was estimated by logistic equation. A continuous score to identify risk-classes was derived according to the model ratios. RESULTS Two-hundred eight patients were studied (median follow-up 20 months). At multivariate analysis, sex, stage, margins, location, nodes, Apc, and Fhit were independent predictors for CSS; the same factors (and age and Her2, except Fhit) predicted OS. Multivariate model predicted IPP with high prognostic accuracy (0.90 for CSS; 0.91 for OS). A two-class model significantly separated low- and high-risk patients for CSS (23.4% and 85.6%, P < 0.0001) and OS (21.4% and 82.0%, P < 0.0001). A three-class model differentiated low-, intermediate-, and high-risk patients for CSS (6.3%, 35.3%, and 88.0%, P < 0.0001) and OS (6.1%, 34.6%, and 86.5%, P < 0.0001). CONCLUSIONS A risk classification system comprising the immunohistochemical expression of three proteins (Apc, Fhit, and Her2) and five clinicopathological parameters (stage, resected nodes, margins, location, and sex) accurately separates the resected gastric cancer patients into three classes of risk.
Collapse
Affiliation(s)
- E Bria
- ARC-NET the Miriam Cherubini Loro, Applied Research on Cancer Center
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Bria E, De Manzoni G, Beghelli S, Tomezzoli A, Barbi S, Frizziero M, Sperduti I, Bersani S, Tortora G, Scarpa A. A Clinico-Molecular Risk Stratification Model for Resected Gastric Cancer: Prognostic Impact of HER2, FHIT and APC Expression Status. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33338-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
4
|
Corbo V, Beghelli S, Bersani S, Antonello D, Talamini G, Brunelli M, Capelli P, Falconi M, Scarpa A. Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Ann Oncol 2012; 23:127-134. [PMID: 21447618 PMCID: PMC3276319 DOI: 10.1093/annonc/mdr048] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2010] [Revised: 01/27/2011] [Accepted: 01/31/2011] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Kinases represent potential therapeutic targets in pancreatic endocrine tumours (PETs). PATIENTS AND METHODS Thirty-five kinase genes were sequenced in 36 primary PETs and three PET cell lines: (i) 4 receptor tyrosine kinases (RTK), epithelial growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), tyrosine-protein kinase KIT (KIT), platelet-derived growth factor receptor alpha (PDGFRalpha); (ii) 6 belonging to the Akt/mTOR pathway; and (iii) 25 frequently mutated in cancers. The immunohistochemical expression of the four RTKs and the copy number of EGFR and HER2 were assessed in 140 PETs. RESULTS Somatic mutations were found in KIT in one and ATM in two primary neoplasms. Among 140 PETs, EGFR was immunopositive in 18 (13%), HER2 in 3 (2%), KIT in 16 (11%), and PDGFRalpha in 135 (96%). HER2 amplification was found in 2/130 (1.5%) PETs. KIT membrane immunostaining was significantly associated with tumour aggressiveness and shorter patient survival. PET cell lines QGP1, CM and BON harboured mutations in FGFR3, FLT1/VEGFR1 and PIK3CA, respectively. CONCLUSIONS Only rare PET cases, harbouring either HER2 amplification or KIT mutation, might benefit from targeted drugs. KIT membrane expression deserves further attention as a prognostic marker. ATM mutation is involved in a proportion of PET. The finding of specific mutations in PET cell lines renders these models useful for preclinical studies involving pathway-specific therapies.
Collapse
Affiliation(s)
- V Corbo
- ARC-NET Center for the Applied Research on Cancer-Networking
| | - S Beghelli
- ARC-NET Center for the Applied Research on Cancer-Networking
| | - S Bersani
- Department of Pathology and Diagnostics
| | - D Antonello
- Department of Surgery and Oncology, University and Hospital Trust of Verona, Verona, Italy
| | - G Talamini
- Department of Surgery and Oncology, University and Hospital Trust of Verona, Verona, Italy
| | | | - P Capelli
- Department of Pathology and Diagnostics
| | - M Falconi
- Department of Surgery and Oncology, University and Hospital Trust of Verona, Verona, Italy
| | - A Scarpa
- ARC-NET Center for the Applied Research on Cancer-Networking; Department of Pathology and Diagnostics.
| |
Collapse
|
5
|
Mercalli A, Sordi V, Formicola R, Dandrea M, Beghelli S, Scarpa A, Di Carlo V, Reni M, Piemonti L. A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. Br J Cancer 2007; 96:1358-67. [PMID: 17426706 PMCID: PMC2360188 DOI: 10.1038/sj.bjc.6603726] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Gemcitabine (GEM)-based chemotherapy is regarded as the standard treatment of pancreatic adenocarcinoma, but yields a very limited disease control. Very few studies have investigated salvage chemotherapy after failure of GEM or GEM-containing chemotherapy and preclinical studies attempting to widen the therapeutic armamentarium, not including GEM, are warranted. MIA PaCa2, CFPAC-1 and Capan-1 pancreatic cancer cell lines were treated with GEM, fluouracil (5-FU), docetaxel (DCT), oxaliplatin (OXP), irinotecan (CPT-11), pemetrexed (PMX) and raltitrexed (RTX) as single agent. Pemetrexed, inducing apoptosis with IC50s under the Cmax in the three lines tested, appeared the most effective drug as single agent. Based on these results, schedule- and concentration-dependent drug interactions (assessed using the combination index) of PMX/GEM, PMX/DCT and PMX-CPT-11 were evaluated. The combinatory study clearly indicated the PMX and CPT-11 combination as the most active against pancreatic cancer. To confirm the efficacy of PMX-CPT-11 combination, we extended the study to a panel of 10 pancreatic cancer cell lines using clinically relevant concentrations (PMX 10 microM; CPT-11 1 microm). In eight of 10 lines, the PMX-CPT-11 treatment significantly reduced cell recovery and increased both the subG1 and caspase 3/7 fraction. After a 5-day wash out period, an increased fraction of subG1 and caspase3/7 persisted in PMX-CPT-11-pretreated cell lines and a significant reduction in the clonogenicity capacity was evident. Finally, in vivo, the PMX/CPT-11 combination showed the ability to inhibit xenograft tumours growth as second-line therapy after GEM treatment. The PMX and CPT-11 combination displays a strong schedule-independent synergistic cytotoxic activity against pancreatic cancer, providing experimental basis for its clinical testing as salvage chemotherapy in pancreatic cancer patients.
Collapse
Affiliation(s)
- A Mercalli
- Laboratory of Experimental Surgery, San Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy
| | - V Sordi
- Laboratory of Experimental Surgery, San Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy
| | - R Formicola
- Laboratory of Experimental Surgery, San Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy
| | - M Dandrea
- Section of Anatomic Pathology, Department of Pathology, University of Verona, Strada Le Grazie 8, Verona 37134, Italy
| | - S Beghelli
- Section of Anatomic Pathology, Department of Pathology, University of Verona, Strada Le Grazie 8, Verona 37134, Italy
| | - A Scarpa
- Section of Anatomic Pathology, Department of Pathology, University of Verona, Strada Le Grazie 8, Verona 37134, Italy
| | - V Di Carlo
- Laboratory of Experimental Surgery, San Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy
| | - M Reni
- Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy
| | - L Piemonti
- Laboratory of Experimental Surgery, San Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy
- E-mail:
| |
Collapse
|
6
|
Pegoraro C, Savio A, Beghelli S, Scarpa A, Zamboni G, Tomba A, Sabbioni R, Merlin F, Cetto GL, Pasini F. Long-term follow-up in low-grade gastric MALT lymphoma (LGGML): Effect of persistent monoclonality (m+) on outcome. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Pegoraro
- University of Verona, Medical Oncology, Verona, Italy; Ospedale S. Orsola, Department of Pathology, Brescia, Italy; University of Verona, Department of Pathology, Verona, Italy; Ospedale di Negrar, Gastroenterology Unit, Verona, Italy
| | - A. Savio
- University of Verona, Medical Oncology, Verona, Italy; Ospedale S. Orsola, Department of Pathology, Brescia, Italy; University of Verona, Department of Pathology, Verona, Italy; Ospedale di Negrar, Gastroenterology Unit, Verona, Italy
| | - S. Beghelli
- University of Verona, Medical Oncology, Verona, Italy; Ospedale S. Orsola, Department of Pathology, Brescia, Italy; University of Verona, Department of Pathology, Verona, Italy; Ospedale di Negrar, Gastroenterology Unit, Verona, Italy
| | - A. Scarpa
- University of Verona, Medical Oncology, Verona, Italy; Ospedale S. Orsola, Department of Pathology, Brescia, Italy; University of Verona, Department of Pathology, Verona, Italy; Ospedale di Negrar, Gastroenterology Unit, Verona, Italy
| | - G. Zamboni
- University of Verona, Medical Oncology, Verona, Italy; Ospedale S. Orsola, Department of Pathology, Brescia, Italy; University of Verona, Department of Pathology, Verona, Italy; Ospedale di Negrar, Gastroenterology Unit, Verona, Italy
| | - A. Tomba
- University of Verona, Medical Oncology, Verona, Italy; Ospedale S. Orsola, Department of Pathology, Brescia, Italy; University of Verona, Department of Pathology, Verona, Italy; Ospedale di Negrar, Gastroenterology Unit, Verona, Italy
| | - R. Sabbioni
- University of Verona, Medical Oncology, Verona, Italy; Ospedale S. Orsola, Department of Pathology, Brescia, Italy; University of Verona, Department of Pathology, Verona, Italy; Ospedale di Negrar, Gastroenterology Unit, Verona, Italy
| | - F. Merlin
- University of Verona, Medical Oncology, Verona, Italy; Ospedale S. Orsola, Department of Pathology, Brescia, Italy; University of Verona, Department of Pathology, Verona, Italy; Ospedale di Negrar, Gastroenterology Unit, Verona, Italy
| | - G. L. Cetto
- University of Verona, Medical Oncology, Verona, Italy; Ospedale S. Orsola, Department of Pathology, Brescia, Italy; University of Verona, Department of Pathology, Verona, Italy; Ospedale di Negrar, Gastroenterology Unit, Verona, Italy
| | - F. Pasini
- University of Verona, Medical Oncology, Verona, Italy; Ospedale S. Orsola, Department of Pathology, Brescia, Italy; University of Verona, Department of Pathology, Verona, Italy; Ospedale di Negrar, Gastroenterology Unit, Verona, Italy
| |
Collapse
|
7
|
Gumbs AA, Moore PS, Falconi M, Bassi C, Beghelli S, Modlin I, Scarpa A. Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. J Surg Oncol 2002; 81:45-53; discussion 54. [PMID: 12210027 DOI: 10.1002/jso.10142] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Pancreatic endocrine neoplasms (PENs) are rare tumors, and little is known about their genetic and chromosomal alterations. Elucidation of the molecular events involved in PEN carcinogenesis has been hindered by the fact that PENs have been considered a single disease entity. The emergence of novel molecular characterization strategies has, however, made it apparent that these lesions exhibit diverse molecular fingerprints, which will facilitate the precise delineation of PEN prognosis, histopathology, and carcinogenesis.
Collapse
Affiliation(s)
- A A Gumbs
- Department of Surgery, University of Verona, Verona, Italy
| | | | | | | | | | | | | |
Collapse
|
8
|
Beghelli S. [Not Available]. Acta Med Hist Patav 2001; 18:9-16. [PMID: 11626111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
|
9
|
Zamboni G, Capelli P, Pesci A, Beghelli S, Lüttges J, Klöppel G. Pancreatic head mass: what can be done? Classification: the pathological point of view. JOP 2000; 1:77-84. [PMID: 11854561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Affiliation(s)
- G Zamboni
- Department of Pathology, University of Verona. Verona, Italy.
| | | | | | | | | | | |
Collapse
|
10
|
Beghelli S, Pelosi G, Zamboni G, Falconi M, Iacono C, Bordi C, Scarpa A. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. J Pathol 1998; 186:41-50. [PMID: 9875139 DOI: 10.1002/(sici)1096-9896(199809)186:1<41::aid-path172>3.0.co;2-l] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Two molecular pathways leading to cancer are known. Common-type cancers arise from the 'tumour suppressor' pathway, characterized by gross chromosomal changes and allelic losses (LOH) in an average of 25 per cent or more of randomly chosen chromosomal loci. The 'mutator pathway' has been recognized in a subset of cancers, characterized by widespread microsatellite DNA instability and rarity of chromosomal losses. The present study has investigated 20 pancreatic endocrine tumours (PETs) for loss of heterozygosity (LOH) at seven chromosomal loci (3p14, 7q31-32, 11q13, 13q14, 18q21, 17p13, and 17q21); microsatellite instability; and Ki-ras, N-ras, and p53 gene mutations. LOH was found in an average of 24 per cent of the chromosomal loci analysed. No tumour showed microsatellite instability. Ki-ras and p53 mutations were each found in one case. The frequency of losses was higher in malignant (40 per cent) than in benign (17 per cent) tumours (p = 0.009), and the specific chromosome 17p13 LOH was associated with extrapancreatic extension of disease (p = 0.007), high proliferative activity (p = 0.001), and absence of progesterone receptors (p = 0.01). A common deleted region on chromosome 17p13 and the rarity of p53 gene mutations suggest the existence of a novel tumour suppressor gene involved in the pathogenesis of PETs in this chromosomal area.
Collapse
Affiliation(s)
- S Beghelli
- Istituto di Anatomia Patologica Università di Verona, Italy
| | | | | | | | | | | | | |
Collapse
|